Background The long-term evidence of ABA for RA patients is limited.
Objectives To assess the long-term safety and efficacy of ABA in patients with RA.
Methods This study consisted of 3 cohorts; Phase I (P1, n=13) and P2 (n=178), ABA10mg/kg + MTX or ABA10mg/kg for 192 wks; new patients (N, n=26), intolerant to MTX due to safety reasons (N). All adverse events and efficacy results were recorded.
Results The average exposure and mean disease duration of 217 patients enrolled in this study was 2.86 and 9.1±7.1 (years), respectively. In total 74.2% patients completed 192 wks period. There was no specific adverse event increased with ABA. The most common AE was nasopharyngitis 56.7%, 46.6 per year of patients. One patient (0.5%) died because of pancreatic carcinoma (causal relationship to study drug:possible). ACR20, DAS28-CRP<2.6, SDAI remission (≤3.3) and Low disease activity (LDA) (≤11) achieved patients ratio increased and maintained steadily and 80.2, 44.7, 12.9 and 52.1% were scored at wks 192, respectively, (Last Observation Carried Forward: LOCF) by the treatment with ABA.
Conclusions During this study, ABA was well tolerated and its efficacy sustained throughout 192 weeks.
Disclosure of Interest None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.